Radiation strategy shows good results in small prostate cancer study

Share this article:

A new treatment protocol that combines intensity-modulated radiation therapy (IMRT) with high-dose-rate (HDR) brachytherapy has been found to be a safe, effective method of radiation dose escalation for localized prostate cancer.

IMRT uses computer-controlled linear accelerators to modulate the intensity of an external radiation beam and deliver radiation to tumors more accurately. In HDR brachytherapy, radioactive pellets are implanted near the tumor. From 2001 through 2006, 26 consecutive men with prostate cancer (T stage ≤2b, prostate-specific antigen ≤20, and Gleason score ≤7) participated in a phase 1/phase 2 trial to examine the toxicity and efficacy of the combination of IMRT and a single-fraction HDR brachytherapy implant.

The treatment, which carried relatively low toxicity, employed a single HDR fraction of 6 Gy to the entire prostate and 9 Gy to the peripheral zone, followed by IMRT delivered in 28 fractions with a normalized total dose of 70 Gy.

The entire set of patients completed the treatment as prescribed, with no cancer recurrence and with a low rate of long-term side effects over a median follow-up period of 53 months (range, 9 to 68 months).

“Our study was designed to reduce radiation exposure to nearby healthy tissue and organs, and we were pleased to find that this unique dosing schedule is safe and effective,” noted Mitchell S. Anscher, MD, in a statement issued by Virginia Commonwealth University (VCU) in Richmond, Virginia. Anscher, the lead author of the study, is the radiation oncology chair as well as a program leader of radiation biology and oncology at the university's Massey Cancer Center, also in Richmond. The protocol was designed by radiation oncologist Michael P. Hagan, MD, PhD, of the Massey Cancer Center. Anscher, Hagan, and colleagues reported their findings in the journal Brachytherapy (2012;11[4]:292-298).

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

More sensitive testing may better define prognosis and treatment for leukemia

Nearly half of patients with the most common form of adult leukemia may have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment.

Doxorubicin-ifosfamide combo improves progression-free survival in soft-tissue sarcoma

A new European study does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma.

New gene implicated in progression and recurrence of triple-negative breast cancer

A gene not previously associated with breast cancer appears to play a pivotal role in the growth and progression of triple-negative breast cancer.